Moderate Buy Lineage Cell Therapeutics Inc. [LCTX] Stock Before Shares Hit Major Turbulence

Lineage Cell Therapeutics Inc. [LCTX] stock is up 4.55 while the S&P 500 has risen 0.66% on Thursday, 12/03/20. While at the time of this article, LCTX ATR is sitting at 0.11, with the beta value at 1.95. This stock’s volatility for the past week remained at 8.37%, while it was 9.07% for the past 30-day period. LCTX has risen $0.07 from the previous closing price of $1.54 on volume of 1.05 million shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 16, November 2020, Lineage Cell Therapeutics Presents New OpRegen® Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting. According to news published on Yahoo Finance, Improved Visual Acuity Continues to be Observed in Cohort 4 Patients.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.53 and a peak of $1.67. Right now, according to Wall Street analyst the average 12-month amount target is $5.00. At the most recent market close, shares of Lineage Cell Therapeutics Inc. [AMEX:LCTX] were valued at $1.61.


Lineage Cell Therapeutics Inc. [AMEX:LCTX] most recently reported quarterly sales of 342.0 million, which represented growth of 0.00%. This publicly-traded organization’s revenue is $26,873 per employee, while its income is -$212,891 per employee. This company’s Gross Margin is currently 85.50%, its Pretax Margin is -1301.35, and its Net Margin is -792.22. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -10.31, -11.32, -33.96 and -11.01 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 4.37 and the whole liability to whole assets at 4.12. It shows enduring liability to the whole principal at 3.34 and enduring liability to assets at 0.03 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.4867 points at 1st support level, the second support level is making up to 1.4333. But as of 1st resistance point, this stock is sitting at 1.5967 and at 1.6533 for 2nd resistance point.

Lineage Cell Therapeutics Inc. [LCTX] reported its earnings at -$0.05 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.04/share signifying the difference of -0.01 and -25.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.04 calling estimates for -$0.04/share with the difference of 0 depicting the surprise of 0.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Lineage Cell Therapeutics Inc. [AMEX:LCTX] is 5.10. Likewise, the Quick ratio is also the same, showing Cash ratio at 4.73. Now if looking for a valuation of this stock’s amount to sales ratio it’s 87.63 and it’s amount to book ratio is 1.18.

Insider Stories

The most recent insider trade was by Lineage Cell Therapeutics, Inc, Previous 10% Owner, and it was the sale of 2.38 million shares on Jan 02.